Full Press Release Details
ASX, Nasdaq and Media Release
Opthea to Participate in the 23rdAnnual Needham Virtual Healthcare Conference
Melbourne, Australia and Princeton, NJ, April 4, 2024 -- Opthea Limited (ASX/NASDAQ: OPT Opthea , the Company ), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference and participate in one-on-one investor meetings on April 11, 2024.
23rd Annual Needham Virtual Healthcare Conference Presentation Details:
| Date: | Thursday, April 11 th |
| Time: | 3:45 p.m. ET |
| Presenter: | Frederic Guerard, Pharm D, CEO |
| Webcast Link | Here |
A webcast of the Needham presentation can be accessed under Events & Presentations in the Investor Relations section of the Company's website, www.opthea.com.
Opthea (ASX:OPT; NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Authorized for release to ASX by Fred Guerard, CEO
| Investor Enquiries | Join our email database to receive program updates: |
| PJ Kelleher LifeSci Advisors Email: pkelleher@lifesciadvisors.com Media Silvana Guerci-Lena NorthStream Global Partners silvana@nsgpllc.com | Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com |